TP53RK

EKC/KEOPS complex subunit TP53RK · Q96S44 · TP53RK on Sugi Atlas →

2,783 patent compounds predicted against TP53RK, 2,079 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Bgt-226 Free Base (SCHEMBL146939)	1.00	1/20
Silmitasertib (SCHEMBL629082)	1.00	1/20
Gsk-1059615 (SCHEMBL1805557)	1.00	1/20
Gsk-1059615 (SCHEMBL1805560)	1.00	1/20
Gsk-1059615 (SCHEMBL1805561)	1.00	1/20
Decernotinib (SCHEMBL2630387)	1.00	1/20
Bgt-226 Free Base (SCHEMBL996046)	0.89	1/20
Bgt-226 Free Base (SCHEMBL996047)	0.89	1/20
SCHEMBL928275	0.86	1/20
SCHEMBL928292	0.84	1/20
SCHEMBL2690879	0.83	1/20
SCHEMBL2630433	0.82	1/20
SCHEMBL928009	0.82	1/20
SCHEMBL2630389	0.81	1/20
SCHEMBL927554	0.81	1/20
SCHEMBL927556	0.81	1/20
SCHEMBL2630384	0.81	1/20
SCHEMBL928827	0.80	1/20
SCHEMBL2630435	0.80	1/20
SCHEMBL2688142	0.80	1/20

Clinical trials — most relevant to TP53RK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer	PHASE2	RECRUITING
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation	PHASE2	UNKNOWN
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer	PHASE2	COMPLETED
Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety	PHASE2	NOT_YET_RECRUITING
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML	PHASE2	COMPLETED
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy	PHASE2	COMPLETED
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer	PHASE1/PHASE2	COMPLETED
Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Safety Study of Infusion of SGT-53 to Treat Solid Tumors	PHASE1	COMPLETED
WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)	PHASE1	RECRUITING
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors	PHASE1	SUSPENDED
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies	PHASE1	COMPLETED
Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage	nan	COMPLETED
Biomarker Monitoring in TP53 Mutation Carriers	nan	COMPLETED
Advanced Refractory Solid Tumors With TP53 Mutations Register Study	nan	UNKNOWN
Molecular Classification in Relation to Prevention of Endometrial Cancer Recurrence and Lifestyle Factors	nan	RECRUITING
LUDEC Study - Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Endometrial Carcinoma	nan	COMPLETED
Prognostic Biomarkers in Patients With Urothelial Carcinoma	nan	COMPLETED
Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome	nan	COMPLETED
Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation	nan	UNKNOWN
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma	nan	COMPLETED
Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Molecular Markers in Cancers and Precancers (MOCA)	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a TP53RK binder may also engage these)

Protein	Name	Similarity
Q99PW4	—	1.000	Q99PW4 →
Q2HGY8	—	0.978	Q2HGY8 →
Q9P7N1	—	0.977	Q9P7N1 →
Q4HYC1	—	0.976	Q4HYC1 →
Q6C2A3	—	0.975	Q6C2A3 →
Q74Z75	—	0.974	Q74Z75 →
Q60560	—	0.973	Q60560 →
Q3U3Q1	—	0.973	Q3U3Q1 →
P40694	—	0.973	P40694 →
ULK3	Serine/threonine-protein kinase ULK3	0.971	landscape →
Q8CG07	—	0.971	Q8CG07 →
Q58H57	—	0.971	Q58H57 →
D3ZHP7	—	0.970	D3ZHP7 →
Q8K370	—	0.970	Q8K370 →
Q6K881	—	0.970	Q6K881 →
Q6CXB9	—	0.970	Q6CXB9 →
Q14147	—	0.970	Q14147 →
Q8C7H1	—	0.970	Q8C7H1 →
Q9NWZ5	—	0.970	Q9NWZ5 →
Q2TAF8	—	0.969	Q2TAF8 →
Q1LVN8	—	0.969	Q1LVN8 →
Q5R6G3	—	0.969	Q5R6G3 →
Q5H8A6	—	0.969	Q5H8A6 →
A2YQ56	—	0.969	A2YQ56 →
F4J8C6	—	0.969	F4J8C6 →
Q9CXF7	—	0.969	Q9CXF7 →
Q0D9V6	—	0.969	Q0D9V6 →
Q9NY93	—	0.969	Q9NY93 →
Q9ZPY9	—	0.969	Q9ZPY9 →
PKLR	Pyruvate kinase PKLR	0.969	landscape →